Skip to main content

Table 1 Epidemiological and clinical characteristics of the population of patients with oropharyngeal carcinoma treated at our center between 2011 and 2021

From: 2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France

Characteristics   No. of patients (%)
   Total cohort p16-positive p16-negative HPV-NA
Number   1365 605 725 35
Age Mean (years) 61.7 61.9 61.7 58.3
Sex Female 291 (21.3%) 130 (21.5%) 154 (21.2%) 7 (20%)
Male 1074 (78.7%) 475 (78.5%) 571 (78.8%) 28 (80%)
Localization Tonsillar fossa 582 (42.6%) 345 (57%) 222 (30.6%) 15 (42.9%)
Tongue base 583 (42.7%) 244 (40.3%) 324 (44.7%) 15 (42.9%)
Soft palate 131 (9.6%) 9 (1.5%) 118 (16.3%) 4 (11.4%)
Pharyngeal wall 69 (5%) 7 (11.6%) 61 (8.4%) 1 (2.9%)
T classification (8th edition) T1 203 (14.9%) 116 (19.2%) 84 (11.6%) 3 (8.6%)
T2 326 (23.9%) 175 (28.9%) 142 (19.6%) 9 (25.7%)
T3 347 (25.4%) 148 (24.5%) 192 (26.5%) 7 (20%)
T4 473 (34.7%) 166 (27.4%) 307 (42.3%) 16 (45.7%)
N classification (7th edition) N0 285 (20.9%) 85 (14%) 195 (26.9%) 5 (14.3%)
N1 191 (14%) 91 (15%) 97 (13.4%) 3 (8.6%)
N2A 88 (6.4%) 57 (9.1%) 27 (3.7%) 4 (11.4%)
N2B 372 (27.3%) 198 (32.2%) 167 (23%) 7 (20%)
N2C 311 (22.8%) 115 (19%) 186 (25.7%) 10 (28.6%)
N3 118 (8.6%) 59 (9.8%) 53 (7.3%) 6 (17.1%)
N classification (8th edition) N0 - 85 (14%) 195 (26.9%) 5 (14.3%)
N1 - 347 (57.4%) 96 (13.2%) -
N2 - 115 (19%) - -
N2A - - 20 (2.8%) -
N2B - - 137 (18.9%) -
N2C - 151 (20.8%) -
N3 - 58 (9.6%) - -
N3A - - 4 (5.5%) -
N3B - - 122 (16.8%) -
M classification M0 1299 (95.2%) 586 (96.9%) 681 (93.9%) 32 (91.4%)
M1 66 (4.8%) 19 (3.1%) 44 (6.1%) 3 (8.6%)
TNM stage (7th edition) Stage I 57 (41.8%) 15 (2.5%) 42 (5.8%) 0
Stage II 77 (56.4%) 23 (3.8%) 52 (7.2%) 2 (5.7%)
Stage III 211 (15.5%) 91 (15%) 117 (16.1%) 3 (8.6%)
Stage IVA 767 (56.2%) 381 (63%) 371 (51.2%) 15 (42.9%)
Stage IVB 187 (13.7%) 76 (12.6%) 99 (13.7%) 12 (34.3%)
Stage IVC 66 (4.8%) 19 (3.1%) 44 (6.1%) 3 (8.6%)
TNM stage (8th edition) Stage I - 118 (19.5%) 42 (5.8%) -
Stage II - 157 (26%) 52 (7.2%) -
Stage III - 311 (51.4%) 115 (15.9%) -
Stage IVA - - 313 (43.2%) -
Stage IVB - - 159 (21.9%) -
Stage IVC - - 44 (6.1%) -
Stage IV - 19 (3.1%)   -
Performance status (WHO) PS 0 1110 (81.3%) 541 (89.4%) 544 (75%) 25 (71.4%)
PS 1 173 (12.7%) 47 (7.8%) 120 (16.6%) 6 (17.1%)
PS 2–4 75 (5.5%) 15 (2.5%) 56 (7.7%) 4 (11.4%)
NA 7 (0.5%) 2 (0.3%) 5 (0.7%) 0